Skip to content

U-TruSignal SpO2 Testing in Neonates

U-TruSignal SpO2 Testing in Neonates

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03383757
Enrollment
117
Registered
2017-12-26
Start date
2017-09-14
Completion date
2019-11-01
Last updated
2020-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulse Oximetry

Brief summary

The purpose of the study is to demonstrate proper function of the U-TruSignal device via clinical performance testing in a neonatal human subject population under standard clinical conditions. A study with human subjects will provide the needed clinical evidence for assessing the accuracy of the pulse oximeter as recommended by the FDA Guidance Document (Pulse Oximeters - Premarket Notification Submissions \[50(k)s\]: Guidance for Industry and Food and Drug Administration Staff.)

Detailed description

The purpose of this study is to collect blood samples from neonates under normal clinical conditions to ensure proper function (clinical performance) with the U-TruSignal device. The study will include both the TruSignal AllFit Sensor and TruSignal Sensitive Sensor. After providing consent, no preparation beyond the investigational site's standard of care is required before study procedures begin. At the start of the procedure, one to two sensors, upon the discretion of the investigator, shall be applied to the subject. The duration of the subject's participation in the study is dependent upon the scheduled routine arterial blood draw and obtaining the maximum of 6 data pairs (3 data pairs per sensor). The Investigator or designated study staff will collect of SpO2 and pulse rate for each study subject. Laboratory results from arterial blood draw will be collected from the hospital's medical records. The description, severity, and device relatedness of any AE or SAE during the study will be recorded.

Interventions

DEVICESpO2 Sensor application & blood draw

At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.

Sponsors

GE Healthcare
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 29 Days
Healthy volunteers
No

Inclusion criteria

1. Parents or legally authorized representative (LAR) can understand and provide written informed consent; AND 2. Subjects are \< 29 days old, and requiring arterial blood samples per the site's standard of care.

Exclusion criteria

1. Neonates with injuries, deformities or abnormalities may prevent proper application of the sensor; 2. Neonates with inadequate heart pump function affecting blood circulation caused by identified cardiac or cardiovascular conditions such as patent ductus arteriosus, persistent pulmonary hypertension, septal defects, or congenital heart disease; 3. Neonates with mean arterial blood pressure \< 20mmHg; 4. Neonates with congenital diaphragmatic hernia; OR 5. Neonates under High frequency ventilation therapy.

Design outcomes

Primary

MeasureTime frameDescription
Accuracy Root Mean Square (ARMS) Per Data Pair30 minutes per data pairCompare observations of Peripheral Capillary Oxygen Saturation (SpO2- measured by the test pulse oximeter system) and Oxygen Saturation of Arterial Blood (SaO2) values (measured by CO-Oximeter analysis of simultaneous drawn arterial blood).

Secondary

MeasureTime frameDescription
Continuous SpO2 Measurements During Data Collection Interval30 minutes per data pairThe secondary objective of the study was to demonstrate U-TruSignal collects substantially continuous SpO2 measurements during a data collection interval. All time the sensors were worn and data collected across participants were reviewed for invalid data within each data pair. For the data pairs that had moments of invalid data, a calculation was conducted (invalid data/complete data for data pair) to establish percentage of invalid data per sensor. For each sensor type the percentage of invalid data (%) was calculated. Sensor readings were grouped together across participants and are being reported as the total number of invalid readings over the total number of readings for all participants

Other

MeasureTime frameDescription
Type and Number of AEs, SAEs, and Device Issues30 minutes per data pairCollect safety information, including type and number of AE s, SAEs, and device issues.

Countries

Finland, India

Participant flow

Participants by arm

ArmCount
SpO2 Sensor Application & Blood Draw
All subjects will undergo the same study procedures of having their SpO2 levels measured with an external sensor applied to the skin and blood SpO2 level measured SpO2 Sensor application & blood draw: At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
78
Total78

Baseline characteristics

CharacteristicSpO2 Sensor Application & Blood Draw
Age, Customized
Age
5.2 days
STANDARD_DEVIATION 4.34
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
36 Participants
Sex: Female, Male
Male
42 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 78
other
Total, other adverse events
0 / 78
serious
Total, serious adverse events
0 / 78

Outcome results

Primary

Accuracy Root Mean Square (ARMS) Per Data Pair

Compare observations of Peripheral Capillary Oxygen Saturation (SpO2- measured by the test pulse oximeter system) and Oxygen Saturation of Arterial Blood (SaO2) values (measured by CO-Oximeter analysis of simultaneous drawn arterial blood).

Time frame: 30 minutes per data pair

Population: Participants may have multiple data points with multiple sensors.

ArmMeasureGroupValue (NUMBER)
SpO2 Sensor Application & Blood DrawAccuracy Root Mean Square (ARMS) Per Data PairTS-AF ARMS2.57 percentage of oxygen saturated hemoglobi
SpO2 Sensor Application & Blood DrawAccuracy Root Mean Square (ARMS) Per Data PairTS-SE ARMS2.57 percentage of oxygen saturated hemoglobi
Secondary

Continuous SpO2 Measurements During Data Collection Interval

The secondary objective of the study was to demonstrate U-TruSignal collects substantially continuous SpO2 measurements during a data collection interval. All time the sensors were worn and data collected across participants were reviewed for invalid data within each data pair. For the data pairs that had moments of invalid data, a calculation was conducted (invalid data/complete data for data pair) to establish percentage of invalid data per sensor. For each sensor type the percentage of invalid data (%) was calculated. Sensor readings were grouped together across participants and are being reported as the total number of invalid readings over the total number of readings for all participants

Time frame: 30 minutes per data pair

Population: 78 Participants analyzed, 38 with TS-AF sensor, 40 with TS-SE sensor. Participants may have multiple data points with multiple sensors.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
SpO2 Sensor Application & Blood DrawContinuous SpO2 Measurements During Data Collection IntervalTS-AF <=1% of invalid data38 Participants
SpO2 Sensor Application & Blood DrawContinuous SpO2 Measurements During Data Collection IntervalTS-AF >1% of invalid data0 Participants
SpO2 Sensor Application & Blood DrawContinuous SpO2 Measurements During Data Collection IntervalTS-SE <=1% of invalid data40 Participants
SpO2 Sensor Application & Blood DrawContinuous SpO2 Measurements During Data Collection IntervalTS-SE >1% of invalid data0 Participants
Other Pre-specified

Type and Number of AEs, SAEs, and Device Issues

Collect safety information, including type and number of AE s, SAEs, and device issues.

Time frame: 30 minutes per data pair

Population: AE, SAE and Device Issues were measured for each sensor.

ArmMeasureGroupValue (NUMBER)
SpO2 Sensor Application & Blood DrawType and Number of AEs, SAEs, and Device IssuesTruSignal AllFit Sensor AE0 Events
SpO2 Sensor Application & Blood DrawType and Number of AEs, SAEs, and Device IssuesTruSignal AllFit Sensor SAE0 Events
SpO2 Sensor Application & Blood DrawType and Number of AEs, SAEs, and Device IssuesTruSignal AllFit Sensor Device Issues0 Events
SpO2 Sensor Application & Blood DrawType and Number of AEs, SAEs, and Device IssuesTruSignal Sensitive Sensor AE0 Events
SpO2 Sensor Application & Blood DrawType and Number of AEs, SAEs, and Device IssuesTruSignal Sensitive Sensor SAE0 Events
SpO2 Sensor Application & Blood DrawType and Number of AEs, SAEs, and Device IssuesTruSignal Sensitive Sensor Device Issues0 Events

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026